Robert-Bosch-Krankenhaus

Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study (2025) Albites-Sanabria J, Palumbo P, Bandinelli S, D’Ascanio I, Mellone S, Paraschiv-Ionescu A, Küderle A, et al. Journal article Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia (2025) Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, et al. Journal article Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer (2025) Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, et al. Journal article The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML (2025) Stasik S, Eckardt JN, Röllig C, Baldus CD, Platzbecker U, Serve H, Müller-Tidow C, et al. Journal article Evaluating the Accuracy and Reliability of Real-World Digital Mobility Outcomes in Older Adults After Hip Fracture: Cross-Sectional Observational Study (2025) Berge MA, Paraschiv-Ionescu A, Kirk C, Küderle A, Micó-Amigo E, Becker C, Cereatti A, et al. Journal article Association between the 400-m walk test and sensor-based daily physical activity in frail and sarcopenic older adults (2025) Rogler J, Krumpoch S, Freiberger E, Lindemann U, Kob R Journal article VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML (2025) Kretschmer L, Ruhnke L, Schliemann C, Fransecky L, Steffen B, Kaufmann M, Burchert A, et al. Journal article Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis (2025) Ronnacker J, Muller PJ, Mikesch JH, Zukunft S, Weinbergerová B, Šrámek J, Valka J, et al. Journal article Associations of family socioeconomic indicators and physical activity of primary school-aged children: a systematic review (2024) Ziegeldorf A, Schoene D, Fatum A, Brauer K, Wulff H Journal article Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia (2024) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Eissymont O, Crysandt M, et al. Journal article